Dr. Saad Usmani of the Levine Cancer Institute in Charlotte, North Carolina, gives his perspective on the treatment options for newly diagnosed as well as relapsed/refractory multiple myeloma patients, as discussed this weekend at the American Society of Hematology (ASH) annual conference in Orlando, Florida.
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content